Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 2FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Other hematologic neoplasm 1Dermatologic 1Classical hematology 1

Conditions

Prostatic Neoplasms 2Prostate Cancer Prevention 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
sulforaphane × Genitourinary × Clear all
NCT04046653 2020-11-18

ADaPT

Quadram Institute Bioscience

Phase NA Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT01265953 2019-05-01

PBroC

Portland VA Medical Center

Phase NA Completed
98 enrolled 10 charts
Genitourinary

Prostate Cancer Prevention

NCT01228084 2017-04-28

Sulforaphane in Treating Patients With Recurrent Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡